William H Rodgers

Dr. William H Rodgers


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
HLHui Li
Hui Li
DLDakai Liu
Dakai Liu
QZQiang Zhou
Qiang Zhou
GRGeorge David Rodriguez
George David Rodriguez
HPHarlan Pietz
Harlan Pietz
WRWilliam H Rodgers
William H Rodgers
Background/Objectives: The COVID-19 pandemic has highlighted the urgent need for rapid, accurate, and accessible diagnostic testing to effectively manage and contain the spread of SARS-CoV-2. RT-PCR is widely recognized as the gold standard for SARS-CoV-2 detection due to its high sensitivity and specificity. However, RT-PCR testing requires specialized laboratory equipment, highly trained personnel, and extended processing times, which limits its feasibility for large-scale screening and point-of-care applications. This study aims to systematically evaluate the diagnostic performance of RT-PCR and a colloidal gold immunochromatographic assay (GICA). Methods: By comparing these two methods, we seek to determine a GICA’s effectiveness as a complementary or alternative diagnostic tool, particularly in resource-limited settings and scenarios requiring rapid, large-scale testing. We assessed the following key clinical parameters: sensitivity, specificity, NPV, PPV, and accuracy. Additionally, we investigated the correlation between GICA signal intensity and RT-PCR Ct values using regression analysis, receiver operating characteristic curve analysis, and the calculated area under the curve. Results: Our findings indicate that while RT-PCR exhibits superior sensitivity, GICA results demonstrate a strong correlation with RT-PCR results and provide a rapid, cost-effective alternative for SARS-CoV-2 detection. Unlike RT-PCR, which requires extensive resources and prolonged turnaround times, a GICA delivers results within 20 min, making it a viable option for decentralized testing and real-time public health interventions. Conclusions: These results suggest that a GICA can serve as a complementary diagnostic tool alongside RT-PCR, particularly in resource-limited settings and high-throughput screening scenarios. By integrating GICAs into broader testing strategies, healthcare systems can enhance early detection efforts, improve accessibility to diagnostics, and strengthen pandemic response measures.

Verified
Journal Article
Open access
PDF file
DLDakai Liu
Dakai Liu
GRGeorge David Rodriguez
George David Rodriguez
HZHang-Yu Zhou
Hang-Yu Zhou
YCYexiao Cheng
Yexiao Cheng
XLXiaofeng Li
Xiaofeng Li
WRWilliam H Rodgers
William H Rodgers
Being in the epicenter of the COVID-19 pandemic, our lab tested 193,054 specimens for SARS-CoV-2 RNA by diagnostic multiplex reverse transcription polymerase chain reaction (mRT-PCR) starting in March 2020, of which 17,196 specimens resulted positive. To investigate the dynamics of virus molecular evolution and epidemiology, whole genome amplification (WGA) and Next Generation Sequencing (NGS) were performed on 9516 isolates. 7586 isolates with a high quality were further analyzed for the mutation frequency and spectrum. Lastly, we evaluated the utility of the mRT-PCR detection pattern among 26 reinfected patients with repeat positive testing three months after testing negative from the initial infection. Our results show a continuation of the genetic divergence in viral genomes. Furthermore, our results indicate that independent mutations in the primer and probe regions of the nucleocapsid gene amplicon and envelope gene amplicon accumulate over time. Some of these mutations correlate with the changes of detection pattern of viral targets of mRT-PCR. Our data highlight the significance of a continuous genetic divergence on a gene amplification-based assay, the value of the mRT-PCR detection pattern for complementing the clinical diagnosis of reinfection, and the potential for WGA and NGS to identify mutation hotspots throughout the entire viral genome to optimize the design of the PCR-based gene amplification assay.

6 October 2025 in Gynecologic Oncology
Verified
Journal Article
Open access
DCDana M. Chase
Dana M. Chase
HHHelen Q. Huang
Helen Q. Huang
WDWei Deng
Wei Deng
WKWui-Jin Koh
Wui-Jin Koh
WRWilliam H Rodgers
William H Rodgers
SRSang Young Ryu
Sang Young Ryu
To prospectively evaluate the impact of adjuvant chemoradiation (RT + CIS) versus radiation (RT) on quality of life (QOL) and patient-reported outcomes (PROs) among patients with intermediate-risk, stage I-IIA cervical cancer treated with radical hysterectomy and pelvic lymphadenectomy. Patients enrolled in GOG-0263 completed PRO/QOL assessments at baseline, 3, 7, and 36 weeks using the FACT-Cx Trial Outcome Index (FACT-Cx TOI), FACT/GOG-Neurotoxicity subscale (FACT/GOG-Ntx-4), the worst pain item from the Brief Pain Inventory (BPI), and five gastrointestinal/genitourinary (GI/GU) symptom items. Linear mixed models adjusted for baseline score, treatment, age, performance status, and country. Among 316 randomized eligible patients (RT + CIS: n = 158; RT: n = 158), questionnaire completion rates were 98 %, 90 %, 88 %, and 81 % at baseline, weeks 3, 7, and 36, respectively. Patients receiving RT + CIS reported a mean FACT-Cx TOI score 5.1 points lower than RT at 3 weeks (97.5 % CI: -8.6 to -1.6; p = 0.004) and 6.3 points lower at 7 weeks (97.5 % CI: -10.2 to -2.4; p = 0.002). By 36 weeks, scores had returned to baseline in both groups, with no significant difference (p = 0.386). Patient-reported neuropathy scores (FACT/GOG-Ntx-4) did not differ significantly between groups at any time point (p = 0.82). Patient-reported GI/GU symptoms and pain worsened at 3 weeks in both arms, followed by recovery to baseline by 36 weeks. QOL declined in both groups after treatment initiation, with greater short-term deterioration in the RT + CIS group. By 36 weeks, QOL and other PROs returned to baseline in both groups. Neuropathy, GI/GU symptoms, and pain showed no significant differences between treatment arms over time.

Verified
Journal Article
Open access
PDF file
DLDakai Liu
Dakai Liu
HLHui Li
Hui Li
XLXiaofeng Li
Xiaofeng Li
GRGeorge David Rodriguez
George David Rodriguez
HPHarlan Pietz
Harlan Pietz
WRWilliam H Rodgers
William H Rodgers
To better understand the vulnerabilities of pregnant women during the COVID-19 pandemic, we conducted a comprehensive, retrospective cohort study to assess differences in immune responses to SARS-CoV-2 infection between pregnant and non-pregnant women. Nasopharyngeal swabs and serum specimens from 90 pregnant and 278 age-matched non-pregnant women were collected from 15 March 2020 to 23 July 2021 at NewYork-Presbyterian Queens Hospital in New York City. Multiplex reverse transcription polymerase chain reaction, neutralizing antibody, and cytokine array assays were used to assess the incidence, viral load, antibody titers and profiles, and examine cytokine expression patterns. Our results show a lower incidence of SARS-CoV-2 infection in pregnant women compared with non-pregnant women. Pregnant women infected with SARS-CoV-2 exhibited a substantially lower viral load. In addition, the levels of both anti-spike protein receptor-binding domain IgG neutralizing antibodies and anti-N Protein IgG were elevated in pregnant women. Finally, cytokine profiling revealed differential expression of leptin across cohorts. These findings suggest that pregnancy is associated with distinct immune and virological responses to SARS-CoV-2 infection, characterized by lower infection rates, substantially lower viral loads, and enhanced antibody production. Differential cytokine expression indicates unique immune modulation in pregnant women.

4 August 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
DLDakai Liu
Dakai Liu
HPHarlan Pietz
Harlan Pietz
GRGeorge David Rodriguez
George David Rodriguez
YWYuexiu Wu
Yuexiu Wu
YCYihan Cao
Yihan Cao
WRWilliam H Rodgers
William H Rodgers
SARS-CoV-2 undergoes frequent mutations that drive viral evolution and genomic diversity, influencing transmissibility, immune escape, and disease severity. In this study, we performed whole-genome sequencing on SARS-CoV-2 isolates from patients in New York City and identified several globally rare mutations across multiple viral lineages. The isolates analyzed for rare mutations belonged to three lineages: B.1.1.7 (Alpha), B.1.526 (Iota), and B.1.623. We identified 16 rare mutations (global incidence <1000) in non-structural protein genes, including nsp2, nsp3, nsp4, nsp6, nsp8, nsp13, nsp14, ORF7a, and ORF8. Three of these mutations—located in nsp2, nsp13, and ORF8—have been reported in fewer than 100 individuals worldwide. We also detected five rare mutations in structural proteins (S, M, and N), including two—one in M and one in N—previously reported in fewer than 100 cases globally. We present clinical profiles of three patients, each infected with genetically distinct viral isolates from the three lineages studied. Furthermore, we illustrate a local transmission chain inferred from unique mutation patterns identified in the Omicron genome. These findings underscore the importance of whole-genome sequencing for detecting rare mutations, tracking community spread, and identifying emerging variants with clinical and public health significance.